FDA clears new device for valve-in-valve TAVR patients at risk of coronary obstruction

Pi-Cardia ShortCut TAVR device. According to Pi-Cardia, ShortCut is the first medical device of its kind; interventional cardiologists use it to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk.

Interventional cardiologists use the ShortCut device to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk. Image courtesy of Pi-Cardia. 

ShortCut, which gained the FDA’s breakthrough device designation back in January, is used to split valve leaflets and reduce the risk of obstruction.